Haleon plc (HLNCF) Stock

About Haleon plc

Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. Its business activities cover extensive regions, including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers various solutions such as oral hygiene products, pain management remedies, respiratory care items, digestive health aids, and a selection of vitamins, minerals, and supplements. Its notable brand collection features Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially named DRVW 2022 plc before officially rebranding to Haleon plc in February 2022. Its main office is situated in Brentford, United Kingdom.

Haleon plc is headquartered in GB.

Haleon plc (HLNCF) stock trades at $4.89 with a market capitalization of $43.03B. The stock is valued at a price-to-earnings (P/E) ratio of 19.68, price-to-book of 1.99, price-to-sales of 2.92. Over the past 52 weeks the stock has ranged between $4.15 and $5.75, and currently trades 15.0% below its 52-week high. It pays a dividend yielding 2.66%.

On profitability, Haleon plc generates a return on equity (ROE) of 10.30%, return on capital employed of 8.71%, an operating margin of 21.87%, a net profit margin of 15.11%.

In its most recent fiscal year, Haleon plc reported annual revenue of $11.0B, net profit of $1.7B, revenue has compounded at 2.2% a year over the last five years, profit at 7.8% a year. Profit growing faster than revenue points to expanding margins.

The balance sheet shows a debt-to-equity ratio of 0.52, a current ratio of 0.92, total assets of $32.6B, $1.3B in cash and equivalents.

HLNCF has an average daily trading volume of 20,352 shares, a beta of 0.24 (less volatile than the overall market).

Official website: www.haleon.com